semaglutide injection mechanism of action of GLP-1 [25] A Pharmacological and Clinical Overview

Looking to take the next step in your wellness journey

What the Research Shows Recent research on semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) has revealed concerning trends about body composition changes: A 2023 analysis of STEP trial data found that approximately 39% of weight lost on semaglutide was lean body mass 1 Research on tirzepatide showed similar patterns, with 30-40% of total weight loss coming from lean tissue 2 Comparative studies indicate GLP-1 users may lose more muscle than people losing weight through diet and exercise alone 3 For context: if you lose 50 pounds on a GLP-1 medication, 15-20 pounds might be muscle mass

Maintaining a balanced perspective is important: metallic taste is not a typical or expected outcome of Ozempic therapy, but individual experiences may vary

Mounjaro slows down how quickly food leaves your stomach